Mylan N.V.’s (MYL) Market Perform Rating Reiterated at Cowen and Company

Mylan N.V. (NASDAQ:MYL)‘s stock had its “market perform” rating reiterated by investment analysts at Cowen and Company in a research report issued to clients and investors on Sunday, May 21st. They presently have a $43.00 target price on the stock, down from their prior target price of $55.00. Cowen and Company’s price target suggests a potential upside of 14.91% from the company’s previous close.

A number of other research analysts have also issued reports on MYL. Mizuho reiterated a “buy” rating and set a $53.00 price target on shares of Mylan N.V. in a research report on Thursday, March 30th. Vetr lowered Mylan N.V. from a “strong-buy” rating to a “buy” rating and set a $44.68 price objective for the company. in a report on Tuesday, February 14th. Deutsche Bank AG cut their target price on Mylan N.V. from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Tuesday, April 18th. Barclays PLC reaffirmed an “equal weight” rating and set a $47.00 target price (up from $44.00) on shares of Mylan N.V. in a research report on Saturday, March 11th. Finally, Zacks Investment Research raised Mylan N.V. from a “sell” rating to a “hold” rating in a research report on Monday, February 27th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $50.77.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Mylan N.V. (NASDAQ:MYL) traded up 0.51% during mid-day trading on Friday, hitting $37.42. 3,739,015 shares of the stock were exchanged. The company has a 50 day moving average of $38.54 and a 200 day moving average of $39.04. Mylan N.V. has a 12-month low of $33.60 and a 12-month high of $50.40. The firm has a market cap of $20.06 billion, a P/E ratio of 37.38 and a beta of 1.23.

Mylan N.V. (NASDAQ:MYL) last posted its quarterly earnings data on Wednesday, May 10th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.01. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The company had revenue of $2.72 billion for the quarter, compared to the consensus estimate of $2.81 billion. During the same period in the previous year, the business earned $0.76 EPS. Mylan N.V.’s revenue for the quarter was up 24.1% compared to the same quarter last year. On average, equities analysts anticipate that Mylan N.V. will post $5.19 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Mylan N.V.’s (MYL) Market Perform Rating Reiterated at Cowen and Company” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://sportsperspectives.com/2017/06/20/mylans-myl-market-perform-rating-reiterated-at-cowen-and-company-updated-updated-updated-updated.html.

In related news, major shareholder Laboratories Abbott sold 44,000,000 shares of Mylan N.V. stock in a transaction dated Thursday, March 23rd. The stock was sold at an average price of $41.60, for a total value of $1,830,400,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Anthony Mauro sold 10,000 shares of Mylan N.V. stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider now directly owns 140,653 shares in the company, valued at approximately $5,626,120. The disclosure for this sale can be found here. Insiders sold a total of 44,035,000 shares of company stock worth $1,831,800,000 over the last quarter. Corporate insiders own 0.69% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. First Personal Financial Services boosted its position in Mylan N.V. by 33.2% in the first quarter. First Personal Financial Services now owns 2,733 shares of the company’s stock worth $107,000 after buying an additional 681 shares during the last quarter. Kernodle & Katon Asset Management Group LLC boosted its position in Mylan N.V. by 4.7% in the third quarter. Kernodle & Katon Asset Management Group LLC now owns 2,884 shares of the company’s stock worth $110,000 after buying an additional 129 shares during the last quarter. Global X Management Co. LLC boosted its stake in shares of Mylan N.V. by 91.6% in the first quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock worth $118,000 after buying an additional 1,441 shares in the last quarter. Ropes Wealth Advisors LLC purchased a new stake in shares of Mylan N.V. during the first quarter worth about $136,000. Finally, Mosaic Family Wealth LLC boosted its stake in shares of Mylan N.V. by 12.5% in the third quarter. Mosaic Family Wealth LLC now owns 3,600 shares of the company’s stock worth $137,000 after buying an additional 400 shares in the last quarter. 69.89% of the stock is currently owned by institutional investors and hedge funds.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply